Brazilian multicenter study on pegvisomant treatment in acromegaly
Autor: | Cesar L. Boguszewski, Martha Katherine P Huayllas, Lucio Vilar, Luciana Ansaneli Naves, Antonio Ribeiro-Oliveira Junior, Beatriz Santana Soares, Mauro Antonio Czepielewski, Julio Abucham, Silvia Regina Correa-Silva, Marcello Delano Bronstein, Raquel Soares Jallad, Felipe Gaia Duarte, Nina Rosa Musolino, Leandro Kasuki, Monica Roberto Gadelha |
---|---|
Jazyk: | angličtina |
Předmět: | |
Zdroj: | Archives of Endocrinology and Metabolism |
Druh dokumentu: | article |
ISSN: | 2359-4292 2359-3997 |
DOI: | 10.20945/2359-3997000000159 |
Popis: | ABSTRACT Objective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with at least two IGF-I measurements on PEGV were included. Efficacy was defined as any normal IGF-I measurement during treatment. Safety data were reviewed. Predictors of response were determined by comparing controlled versus uncontrolled patients. Results 109 patients [61 women; median age at diagnosis 34 years; 95.3% macroadenomas] from 10 Brazilian centers were studied. Previous treatment included surgery (89%), radiotherapy (34%), somatostatin receptor ligands (99%), and cabergoline (67%). Before PEGV, median levels of GH, IGF-I and IGF-I % of upper limit of normal were 4.3 µg/L, 613 ng/mL, and 209%, respectively. Pre-diabetes/diabetes was present in 48.6% and tumor remnant in 71% of patients. Initial dose was 10 mg/day in all except 4 cases, maximum dose was 30 mg/day, and median exposure time was 30.5 months. PEGV was used as monotherapy in 11% of cases. Normal IGF-I levels was obtained in 74.1% of patients. Glycemic control improved in 56.6% of patients with pre-diabetes/diabetes. Exposure time, pre-treatment GH and IGF-I levels were predictors of response. Tumor enlargement occurred in 6.5% and elevation of liver enzymes in 9.2%. PEGV was discontinued in 6 patients and 3 deaths unrelated to the drug were reported. Conclusions In a real-life scenario, PEGV is a highly effective and safe treatment for acromegaly patients not controlled with other therapies. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |